NUFLOR GOLD - florfenicol injection Schering Corporation

Similar documents
CEFA-DROPS AND CEFA-TABS

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

Focus on Preventing Disease. keeping an eye on a healthy bottom line. Cattle Industry

Dechra Veterinary Products Limited (A business unit of Dechra Pharmaceuticals PLC) Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS

skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by susceptible strains of organisms.

ZOVIRAX Cold Sore Cream

MUTUAL RECOGNITION PROCEDURE DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Report of the Veal Calf Vaccination Study with Rispoval IntraNasal (Zoetis)

Summary of Product Characteristics

Public Assessment Report. Decentralised Procedure

MATERIAL SAFETY DATA SHEET

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

PACKAGE LEAFLET. CLINDAMYCIN capsules Clidamycin. One capsule of 75 mg contains 75 mg Clindamycin (as hydrochloride).

Animalgeiscs for Mice & Rats, 3.0 ml Vial Label: Carton Label:

Vaccination Programs for the Cow/Calf Operation

Reconstitution of Solutions

Diagnostic Testing and Strategies for BVDV

IVOMEC EPRINEX (eprinomectin) Pour-On for Beef and Dairy Cattle

VACCINATION PROGRAMS FOR DAIRY YOUNG STOCK

The clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.

Guidance for Industry

PRIORITY RESEARCH TOPICS

MATERIAL SAFETY DATA SHEET

SUMMARY OF PRODUCT CHARACTERISTICS

MATERIAL SAFETY DATA SHEET SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION

GUIDELINES FOR THE REGISTRATION OF BIOLOGICAL PEST CONTROL AGENTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS

ALLERGENIC EXTRACT. Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE. U.S. Government License No.

Nursing 113. Pharmacology Principles

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

POISON KEEP OUT OF REACH OF CHILDREN READ SAFETY DIRECTIONS BEFORE OPENING OR USING FOR ANIMAL TREATMENT ONLY. As an aid in the control of bloat.

ROFERON-A PFS 3 M IU/0.5 ml

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Don t gamble on your HERD S health.

IV solutions may be given either as a bolus dose or infused slowly through a vein into the plasma at a constant or zero-order rate.

CODE OF PRACTICE TO MINIMIZE AND CONTAIN ANTIMICROBIAL RESISTANCE CAC/RCP

reduce the probability of devastating disease outbreaks reduce the severity of disease agents present in a herd improve the value of products sold.

FAQs on Influenza A (H1N1-2009) Vaccine

Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania SUMMARY OF PRODUCT CHARACTERISTICS

New 7/1/2015 MCFRS 1

DO YOU HAVE ITCHY ALLERGY EYES? Find out about lasting relief

1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Conclusion No cytotoxicity can be detected at concentrations up to 100%.

Consumer Concerns About Hormones in Food

MATERIAL SAFETY DATA SHEET

SUMMARYOF PRODUCT CHARACTERISTICS

160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection.

Chapter 15. Reconstitution and Dosages Measured in Units. Copyright 2012, 2007 Mosby, Inc., an affiliate of Elsevier Inc. All rights reserved.

Dacarbazine for Injection, USP Dacarbazine Antineoplastic

National Antimicrobial Resistance Monitoring System - Enteric Bacteria. A program to monitor antimicrobial resistance in humans and animals

8/6/2010. Name of medication Concentration (1:1,000 or 1mg/1ml) Expiration date

Clinical Study Synopsis for Public Disclosure

MATERIAL SAFETY DATA SHEET Utrecht Gesso Painting Grounds. Section 2 Hazard Identification (composition / information on ingredients)

PROCESS FLOW DIAGRAM Figure 1

WARNING LETTER. According to its approved product labeling (PI) (in pertinent part, emphasis original):

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Tobramycin Injection, USP Tobramycin Sulfate Anti-Infective

Reference ID:

Basic Overview of Preclinical Toxicology Animal Models

Facts About Brucellosis

VACCINATION PROGRAM FOR BEEF CALVES

MATERIAL SAFETY DATA SHEET

Professional Biological Company Since 1923

Emergency Telephone (800)

Epinephrine Administration Training for Unlicensed School Personnel

3M TM DuraPrep TM Surgical Solution (Iodine Povacrylex [0.7% available iodine] and Isopropyl Alcohol, 74% w/w) Patient Preoperative Skin Preparation

Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV

MATERIAL SAFETY DATA SHEET Complies with ANSI Z400.1 Format SECTION 1: PRODUCT IDENTIFICATION

COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

Biological Sciences Initiative

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET

Prior Authorization Guideline

PRODUCT ID: LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION

Re: GRAS Notice No. AGRN

Version: 1.0 Revision Date: 06/25/2013 Print Date: 06/25/2013 POOL TIME D.E. FILTER POWDER

One vial contains 500 U* of C1-inhibitor** After reconstitution the product contains 500 U/5 ml which correspond to a concentration of 100 U/ml.

Minimizing Occupational Exposure to Hazardous Chemicals in Animal Protocols

SUMMARY OF PRODUCT CHARACTERISTICS. Buprenovet 0.3 mg/ml Solution for Injection for Dogs and Cats (AT, DE)

Epinephrine Administration by the EMT

Improves pig performance in a wide range of health and growing conditions

Revised: 9/2014. LUMIGAN (bimatoprost ophthalmic solution) 0.01% for topical ophthalmic use. Initial U.S. Approval: 2001

OFF! DEEP WOODS SPORTSMEN INSECT REPELLENT I (PUMP SPRAY)

RECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS

MATERIAL SAFETY DATA SHEET

New product approval for Fixed-Time AI. John Lee, DVM Zoetis Dairy Technical Services

IMPORTANT: PLEASE READ

SUMMARY OF PRODUCT CHARACTERISTICS

Recommendations for the Safe Use of Handling of Cytotoxic Drugs

MagExtractor -Genome-

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Faculteit Diergeneeskunde. Prof. dr. G. Opsomer Faculty of Veterinary Medicine Ghent University.

September 19, 1984 FOOD PRODUCTION AND DIRECTION GÉNÉRALE, SECTION INSPECTION BRANCH PRODUCTION ET INSPECTION PESTICIDES DES ALIMENTS TRADE MEMORANDUM

VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension

STATE FFA DAIRY EVALUATION CAREER DEVELOPMENT EVENT KNOWLEDGE TEST

Medication Guide Rebif (Re-bif) Interferon beta-1a (in-ter-feer-on beta-one-â)

MATERIAL SAFETY DATA SHEET

Item 2 Guidelines for the Production of Polyclonal and Monoclonal Antibodies in Rodents and Rabbits

Preconditioning programs for healthier, higher-value calves

Transcription:

NUFLOR GOLD - florfenicol injection Schering Corporation 300 mg/ml Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal PRODUCT INFORMATION CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION NUFLOR GOLD is an injectable solution of the synthetic antibiotic florfenicol. Each milliliter of sterile NUFLOR GOLD contains 300 mg of florfenicol, 300 mg of 2-pyrrolidone, and triacetin qs. INDICATION NUFLOR GOLD is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in beef and non-lactating dairy cattle. DOSAGE AND ADMINISTRATION NUFLOR GOLD should be administered once by subcutaneous injection at a dose rate of 40 mg florfenicol/kg body weight (6 ml/100 lb). Do not administer more than 15 ml at each site. The injection should be given only in the neck. Injection sites other than the neck have not been evaluated. NUFLOR GOLD Dosage Guide ANIMAL WEIGHT (lb) DOSAGE (ml) 100 6.0 200 12.0 300 18.0 400 24.0 500 30.0 600 36.0 700 42.0 800 48.0 900 54.0 1000 60.0 CONTRAINDICATIONS Do not use in animals that have shown hypersensitivity to florfenicol. Recommended Injection Location: WARNINGS NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. This product contains materials that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information. For customer service, to report suspected adverse reactions, or to obtain a copy of the MSDS, call 1-800-211-3573. PRECAUTIONS Not for use in animals intended for breeding purposes. The effects of florfenicol on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy. Subcutaneous injection in cattle can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter. page 1 of 5

RESIDUE WARNINGS Animals intended for human consumption must not be slaughtered within 44 days of treatment. Do not use in female dairy cattle 20 months of age or older. Use of florfenicol in this class of cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal. ADVERSE REACTIONS Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle. In addition, anaphylaxis and collapse have been reported post-approval with the use of another formulation of florfenicol in cattle. CLINICAL PHARMACOLOGY The pharmacokinetic disposition of NUFLOR GOLD was evaluated in feeder calves following a single subcutaneous injection at a dose rate of 40 mg florfenicol/kg body weight. Administration of NUFLOR GOLD resulted in florfenicol plasma concentrations of 2 µg (mcg)/ml within two hours of injection. Table 1. Pharmacokinetic Parameter Values for Florfenicol Following a Single Subcutaneous Injection of NUFLOR GOLD at a Dose Rate of 40 mg Florfenicol/kg Body Weight to Feeder Calves (n=24). C max T max (hr) AUC last (µg*hr/ml) n 24 24 24 23 * Mean 5.93 5 150 37.7 % CV 38.3 2-12 20.9 27.3 C max : Maximum observed plasma concentration T max : Time at which C max was observed AUC last : Area under the plasma-concentration-time curve from time zero to the last quantifiable concentration that is equal to or greater than the limit of quantification of the validated analytical method T ½ : Terminal elimination half-life % CV: Percent coefficient of variance *T ½ value could not be accurately estimated for one calf T max is presented as the median value or range of observed values (minimum to maximum) Figure 1. Mean Florfenicol Plasma Concentration versus Time Following a Single Subcutaneous Injection of NUFLOR GOLD at a Dose Rate of 40 mg Florfenico/kg Body Weight in Feeder Calves (Mean ± Standard Error of the Mean) T½ (hr) MICROBIOLOGY Florfenicol is a synthetic, broad-spectrum antibiotic active against many Gram-negative and Gram-positive bacteria isolated from domestic animals. It acts by binding to the 50S ribosomal subunit and inhibiting bacterial protein synthesis. Florfenicol is generally considered a bacteriostatic drug, but it exhibits bactericidal activity against certain bacterial species. In vitro studies demonstrate that florfenicol is active against the BRD pathogens M. haemolytica, P. multocida, H. somni, and M. bovis and that florfenicol exhibits bactericidal activity against strains of M. haemolytica and H. somni. The minimum inhibitory concentrations (MICs) of florfenicol were determined for BRD isolates obtained from calves enrolled in BRD field studies in the U.S. in 2006 using methods recommended by the Clinical and Laboratory Standards Institute (M31-A2). Isolates were obtained from pre-treatment nasal swabs from all calves enrolled at all four sites, post-treatment nasal swabs from treatment failures in the NUFLOR GOLD Injectable Solution and saline control treatment groups at three sites, and lung tissue from one calf that died in the saline control treatment group. The results are shown below in Table 2. page 2 of 5

Table 2. Florfenicol MIC values * of indicated pathogens isolated from cattle with naturally-occurring BRD Indicated pathogens Year of isolation No. of isolates MIC 50 MIC 90 MIC range Mannheimia haemolytica 2006 158 1.0 1.0 0.5 to 32 Pasteurella multocida 2006 103 0.5 0.5 0.125 to 16 Histophilus somni 2006 85 0.125 0.125 0.125 to 0.25 *The correlation between in vitro susceptibility data and clinical effectiveness is unknown. The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively. ANIMAL SAFETY A target animal safety study was conducted to evaluate the effects of NUFLOR GOLD when administered to feeder cattle by subcutaneous injection at 1X, 3X, or 5X the labeled dose for three consecutive days (3X the labeled duration). Decreased feed consumption (inappetence), decreased water consumption, and injection site swelling were observed in the 1X, 3X, and 5X groups. A separate injection site study conducted in cattle demonstrated that NUFLOR GOLD may induce a transient local reaction in the subcutaneous tissue and underlying muscle tissue. STORAGE INFORMATION Store between 2-30 C (36-86 F). Use within 28 days of first use. Refrigeration is not required. The solution is light yellow to straw colored. Color does not affect potency. HOW SUPPLIED NUFLOR GOLD is packaged in 100 ml (NDC 0061-5327-01), 250 ml (NDC 0061-5327-02), and 500 ml (NDC 0061-5327-03) glass sterile multiple-dose vials. Made in Germany Inc., Roseland, NJ 07068 2009, Inc. All rights reserved. B-31331005 7/09 F-31331005. PRINCIPAL DISPLAY PANEL - 100 ML VIAL LABEL Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian NDC 0061-5327-01 100 ml Multiple Dose Vial 300 mg/ml Sterile PRINCIPAL DISPLAY PANEL - 100 ML VIAL CARTON Injectable Solution, page 3 of 5

An Antimicrobial Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian NDC 0061-5327-01 100 ml Multiple Dose Vial 300 mg/ml Sterile PRINCIPAL DISPLAY PANEL - 250 ML VIAL LABEL Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian NDC 0061-5327-02 250 ml Multiple Dose Vial 300 mg/ml Sterile PRINCIPAL DISPLAY PANEL - 500 ML VIAL LABEL Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian page 4 of 5

NDC 0061-5327-03 500 ml Multiple Dose Vial 300 mg/ml Sterile page 5 of 5